Mortality was reported in eleven studies, while the rest of the eighty eight trials did not mention death. Effect rate was assessed in all the trials, based on the improvement of heart function. Ninety one trials used New York Heart Association (NYHA) Classification of Clinical Status, and six trials used Killip's Rating Standards [22, 25, 26, [33] [34] [35] for diagnosing HF and rating the patients. Patients in fifty one trails ranged from II to IV, seven trials II to III, twenty one trials III to IV, and five trials IV according to NYHA Classification; patients in five trials ranged from II to IV and one trial IV according to Killip's Standard.